Dashboard
Manage Tickers

ZLAB Zai Lab Ltd

Nasdaq zailaboratory.com


$ 25.45 $ -0.93 (-3.53 %)    

Tuesday, 28-Oct-2025 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 633.40 $ 4.83 (0.77 %)
DIA $ 476.74 $ 1.80 (0.38 %)
SPY $ 687.16 $ 1.82 (0.27 %)
TLT $ 92.10 $ 0.24 (0.26 %)
GLD $ 363.70 $ -2.63 (-0.72 %)
$ 25.41
$ 25.92
$ 25.00 x 426
$ 26.73 x 50
$ 25.31 - $ 26.14
$ 23.82 - $ 44.34
1,275,238
na
38.66B
$ 1.13
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-01-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

zai-lab-demonstrates-robust-durable-responses-in-phase-1-clinical-study-of-zocilurtatug-pelitecan-in-pre-treated-participants-with-extensive-stage-small-cell-lung-cancer-across-six-dose-groups
Zai Lab Demonstrates Robust, Durable Respo...
10/24/2025 13:10:40

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug ...

zai-lab-reveals-oral-presentation-of-updated-data-from-global-phase-1-trial-of-zocilurtatug-pelitecan-zl-1310-a-potential-first-in-class-dll3-targeted-adc-at-2025-aacr-nci-eortc-conference
Zai Lab Reveals Oral Presentation Of Updat...
10/13/2025 16:07:44

- Oral presentation to feature new data highlighting the potential of zocilurtatug pelitecan (formerly called ZL-1310) as a pro...

zai-labs-double-whammy-earnings-miss-phase-3-setback
Zai Lab's Double Whammy: Earnings Miss, Ph...
09/11/2025 12:02:01

amgen-faces-setback-as-final-data-weakens-case-for-gastric-cancer-drug
Amgen Faces Setback As Final Data Weakens ...
09/04/2025 18:35:12

Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to th...

c3ai-posts-downbeat-results-joins-gitlab-salesforce-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
C3.ai Posts Downbeat Results, Joins GitLab...
09/04/2025 12:17:31

reported-sunday-zai-lab-announces-hong-kong-approval-of-tivdak-for-adult-patients-with-recurrent-or-metastatic-cervical-cancer-after-chemotherapy
Reported Sunday, Zai Lab Announces Hong Ko...
09/02/2025 07:12:46

zai-lab-granted-innovative-medical-device-designation-by-china-national-medical-products-administration-for-tumor-treating-fields-in--pancreatic-cancer
Zai Lab Granted Innovative Medical Device ...
08/19/2025 11:31:42

citigroup-maintains-buy-on-zai-lab-raises-price-target-to-69
Citigroup Maintains Buy on Zai Lab, Raises...
08/11/2025 13:15:48

Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and raises the price target from $66 to $69.

zai-lab-affirms-fy2025-sales-guidance-of-560000m-590000m-vs-567559m-est
Zai Lab Affirms FY2025 Sales Guidance of $...
08/07/2025 10:15:01

Zai Lab (NASDAQ:ZLAB) affirms FY2025 sales outlook from $560.000 million-$590.000 million to $560.000 million-$590.000 million ...

zai-lab-q2-eps-037-beats-040-estimate-sales-109977m-miss-125628m-estimate
Zai Lab Q2 EPS $(0.37) Beats $(0.40) Estim...
08/07/2025 10:01:27

Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.40) by 7....

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

netflix-blacksky-technology-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Netflix, BlackSky Technology And Other Big...
07/18/2025 12:48:42

leerink-partners-maintains-outperform-on-zai-lab-raises-price-target-to-75
Leerink Partners Maintains Outperform on Z...
06/30/2025 18:43:35

Leerink Partners analyst Jonathan Chang maintains Zai Lab (NASDAQ:ZLAB) with a Outperform and raises the price target from $...

amgens-gastric-cancer-drug-improves-survival-in-phase-3-notes-ocular-side-effects
Amgen's Gastric Cancer Drug Improves Survi...
06/30/2025 16:53:02

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

zai-lab-says-phase-3-fortitude-101-clinical-trial-evaluating-first-line-bemarituzumab-plus-chemotherapy-meets-primary-endpoint-of-overall-survival-at-pre-specified-interim-analysis
Zai Lab Says Phase 3 FORTITUDE-101 Clinica...
06/30/2025 13:12:54

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpre...

zai-lab-unveils-new-atopic-dermatitis-drug-that-blocks-both-itch-and-inflammation-for-over-3-months-in-study
Zai Lab Unveils New Atopic Dermatitis Drug...
06/13/2025 11:04:07

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced new data from its preclinical study of ZL-1503, the Company's p...

applied-digital-and-riot-platforms-are-among-top-10-mid-cap-gainers-last-week-jun-2-jun-6-are-the-others-in-your-portfolio
Applied Digital And Riot Platforms Are Amo...
06/08/2025 15:45:33

guidewire-software-posts-upbeat-q3-results-joins-yext-rev-group-and-other-big-stocks-moving-higher-on-wednesday
Guidewire Software Posts Upbeat Q3 Results...
06/04/2025 15:37:54

novocures-tumor-treating-fields-boost-one-year-and-pain-free-survival-in-pancreatic-cancer-trial
NovoCure's Tumor Treating Fields Boost One...
06/02/2025 18:05:17

TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data fr...

zai-lab-limited-announced-that-updated-data-from-an-ongoing-global-phase-1a1b-clinical-trial-nct06179069-evaluating-zocilurtatug-pelitecan-or-zl-1310-the-companys-potential-first-in-class-delta-like-ligand-dll3-antibody-drug-conjugate-adc-for-patients-with-extensive-stage-small-cell-lung-cancer-es-sclc
Zai Lab Limited Announced That Updated Dat...
06/02/2025 11:11:14

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION